Search Results

CytoSorbents Corporation announces the regulatory approval of CytoSorb® in Taiwan by the Taiwan Food and Drug Administration (TFDA).

TLC BioSciences announced that the Abstract Selection Committee of the American College of Rheumatology has accepted TLC’s late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023.

TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.

Co-Diagnostics, Inc. announced that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan.

Rigaku, a global solution partner in X-ray-analysis proudly announces the opening of its new Rigaku Taiwan Branch.

TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.

Sol-Gel Technologies, Ltd. announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.